WO2022219546 - HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H
National phase entry:
Publication Number
WO/2022/219546
Publication Date
20.10.2022
International Application No.
PCT/IB2022/053454
International Filing Date
13.04.2022
Title **
[English]
HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H
[French]
DÉRIVÉS D'HÉTÉROARYL-AMINOPROPANOL EN TANT QU'INHIBITEURS DE LTA4H
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
KORDIKOWSKI, Andreas
Novartis Pharma AG, Postfach
4002 Basel, CH
LIU, Yugang
Novartis Pharmaceuticals Corporation, One Health Plaza
East Hanover, New Jersey 07936-1080, US
LÜÖND, Rainer Martin
Novartis Pharma AG, Postfach
4002 Basel, CH
MARKERT, Christian
Novartis Pharma AG, Postfach
4002 Basel, CH
MILTZ, Wolfgang
Oberwilerstrasse 30
4123 Allschwill, CH
ROEHN, Till
Novartis Pharma AG, Postfach
4002 Basel, CH
SPANKA, Carsten
Novartis Pharma AG, Postfach
4002 Basel, CH
THOMA, Gebhard
Novartis Pharma AG, Postfach
4002 Basel, CH
XIE, Tian
China Novartis Institutes for BioMedical Research Co., Ltd.
4218 Jinke Road ZhangJiang Hi-Tech Park
Pudong, Shanghai 201203, CN
Priority Data
PCT/CN2021/087655
16.04.2021
CN
63/311,231
17.02.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2313 | |
| EPO | Filing, Examination | 9179 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 4410 |
Total: 17095 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present application relates to Leukotriene A4 hydrolase (LTA4H) inhibitors of formula (I), for use in the treatment of various disorders.[French]
La présente invention concerne des inhibiteurs de leucotriène A4 hydrolase (LTA4H) de formule (I), destinés à être utilisés dans le traitement de divers troubles.